Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma

E-ISSN： 1873-4316|1|4|303-312

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.1, Iss.4, 2000-12, pp. : 303-312

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituxan® Immunotherapy and Zevalin® Radioimmunotherapy in the Treatment of Non-Hodgkin's Lymphoma

Current Pharmaceutical Biotechnology, Vol. 4, Iss. 4, 2003-08 ,pp. : 221-238

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkin's Lymphoma

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 301-311

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody-Targeted Immunoliposomes for Cancer Treatment

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 2026-2035

Bentham Science Publishers

Access to resources Recommend Favorite

Non-Hodgkin's Lymphoma: Review of Conventional Treatments

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 279-291

Bentham Science Publishers

Access to resources Recommend Favorite

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite